NEI
ABVX

Northwest & Ethical Investments’s Abivax ABVX Stock Holding History

Northwest & Ethical Investments’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.9K Buy
+467
New +$52.9K ﹤0.01% 508

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northwest & Ethical Investments's ABVX Position: Q2 2026 in Review

Northwest & Ethical Investments opened a new position in Abivax (ABVX) in Q2 2026: 467 shares worth $44.9K. The stake represents ﹤0.01% of the portfolio and ranks #508 among its holdings.

302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Northwest & Ethical Investments held 467 shares of Abivax worth $44.9K as of Q2 2026.
  • Abivax was a new Northwest & Ethical Investments position in Q2 2026.
  • Abivax made up ﹤0.01% of Northwest & Ethical Investments's portfolio in Q2 2026, its #508 holding.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.